Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)
Phase 2
Withdrawn
- Conditions
- HIV/AIDSHIV-1-infectionOsteopenia
- Interventions
- Drug: Current tenofovir alafenamide (TAF)-containing ART regimen
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Philip Grant
- Registration Number
- NCT03549689
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
Phase 2
Completed
- Conditions
- HIV
- Interventions
- Drug: Rilpivirine/Emtricitabine/Tenofovir
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Philip Grant
- Target Recruit Count
- 150
- Registration Number
- NCT02104700
- Locations
- 🇷🇼
Rwanda Military Hospital, Kinombe, Rwanda
News
No news found